201 related articles for article (PubMed ID: 22995770)
1. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
Zang Y; Thomas SM; Chan ET; Kirk CJ; Freilino ML; DeLancey HM; Grandis JR; Li C; Johnson DE
Autophagy; 2012 Dec; 8(12):1873-4. PubMed ID: 22995770
[TBL] [Abstract][Full Text] [Related]
2. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Zang Y; Kirk CJ; Johnson DE
Cancer Biol Ther; 2014 Sep; 15(9):1142-52. PubMed ID: 24915039
[TBL] [Abstract][Full Text] [Related]
3. Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.
Zang Y; Thomas SM; Chan ET; Kirk CJ; Freilino ML; DeLancey HM; Grandis JR; Li C; Johnson DE
Clin Cancer Res; 2012 Oct; 18(20):5639-49. PubMed ID: 22929803
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation.
Li C; Johnson DE
Cancer Lett; 2012 Jan; 314(1):102-7. PubMed ID: 21993018
[TBL] [Abstract][Full Text] [Related]
5. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
[TBL] [Abstract][Full Text] [Related]
6. Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma.
Vandewynckel YP; Coucke C; Laukens D; Devisscher L; Paridaens A; Bogaerts E; Vandierendonck A; Raevens S; Verhelst X; Van Steenkiste C; Libbrecht L; Geerts A; Van Vlierberghe H
Oncotarget; 2016 Jun; 7(23):34988-5000. PubMed ID: 27167000
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
Li C; Li R; Grandis JR; Johnson DE
Mol Cancer Ther; 2008 Jun; 7(6):1647-55. PubMed ID: 18566236
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.
Fribley A; Zeng Q; Wang CY
Mol Cell Biol; 2004 Nov; 24(22):9695-704. PubMed ID: 15509775
[TBL] [Abstract][Full Text] [Related]
9. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.
Li C; Zang Y; Sen M; Leeman-Neill RJ; Man DS; Grandis JR; Johnson DE
Mol Cancer Ther; 2009 Aug; 8(8):2211-20. PubMed ID: 19638453
[TBL] [Abstract][Full Text] [Related]
11. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
Leukemia; 2013 Feb; 27(2):430-40. PubMed ID: 22763387
[TBL] [Abstract][Full Text] [Related]
12. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.
Milani M; Rzymski T; Mellor HR; Pike L; Bottini A; Generali D; Harris AL
Cancer Res; 2009 May; 69(10):4415-23. PubMed ID: 19417138
[TBL] [Abstract][Full Text] [Related]
13. Second Generation Proteasome Inhibitors in Multiple Myeloma.
Gozzetti A; Papini G; Candi V; Brambilla CZ; Sirianni S; Bocchia M
Anticancer Agents Med Chem; 2017; 17(7):920-926. PubMed ID: 27592543
[TBL] [Abstract][Full Text] [Related]
14. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
[TBL] [Abstract][Full Text] [Related]
15. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
Vogl DT; Stadtmauer EA; Tan KS; Heitjan DF; Davis LE; Pontiggia L; Rangwala R; Piao S; Chang YC; Scott EC; Paul TM; Nichols CW; Porter DL; Kaplan J; Mallon G; Bradner JE; Amaravadi RK
Autophagy; 2014 Aug; 10(8):1380-90. PubMed ID: 24991834
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.
Kao C; Chao A; Tsai CL; Chuang WC; Huang WP; Chen GC; Lin CY; Wang TH; Wang HS; Lai CH
Cell Death Dis; 2014 Nov; 5(11):e1510. PubMed ID: 25375375
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.
Obeng EA; Carlson LM; Gutman DM; Harrington WJ; Lee KP; Boise LH
Blood; 2006 Jun; 107(12):4907-16. PubMed ID: 16507771
[TBL] [Abstract][Full Text] [Related]
18. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079
[TBL] [Abstract][Full Text] [Related]
19. Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs.
Hasinoff BB; Patel D
Cardiovasc Toxicol; 2018 Dec; 18(6):557-568. PubMed ID: 29951728
[TBL] [Abstract][Full Text] [Related]
20. Advances in the understanding of mechanisms and therapeutic use of bortezomib.
Mujtaba T; Dou QP
Discov Med; 2011 Dec; 12(67):471-80. PubMed ID: 22204764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]